TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Market Closed - Deutsche Boerse AG 15:37:02 2024-05-31 EDT | ||
| 13.35 EUR | -1.26% |
|
| 1 month | +0.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 13.35 | -1.26% |
| 24-05-30 | 13.52 | -1.02% |
| 24-05-29 | 13.66 | +1.11% |
| 24-05-28 | 13.51 | +1.43% |
| 24-05-27 | 13.32 | -3.06% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 03:37 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88X1 |
| ISIN | DE000SW88X18 |
| Date issued | 2024-04-19 |
| Strike | 2,932 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.93 € |
|---|---|
| Lowest since issue | 11.75 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
